Genoox for Oncology

Accelerated analysis and identification for timely diagnosis and treatment

Oncology Applications

disease screening - Oncology applications


Advanced Disease Screening

How Can We Help?

Genoox offers a full range of WES to single gene platforms designed for oncologists to determine risk assessment for a variety of inherited cancer risk genes
Clear, easy to read clinical reports simply patient/physician discussions

- Access advanced preventive tools
- Assess disease risk for a broad range of inherited cancer risk genes using a full range of WES or single gene platforms
- Simplify patient/physician discussions with clear and concise reports
companion diagnostic prediction - Oncology applications

Diagnostic Tools

Advanced Diagnostic Tools

How Can We Help?

We help identify and confirm the existence of a cancer and distinguish between benign and malignant disease, as well to support the diagnosis or in follow-up of patients being treated for cancer

- Rapidly identify and confirm the existence of a cancer
- Distinguish between benign and malignant disease
- Enhance patient treatment and follow-up
cancer risk assessment - Oncology applications

Therapy response prediction

Therapy response prediction

How Can We Help?

There are increasing numbers of drugs and treatments for cancer that are given based on genetic biomarkers. In addition, there are somatic mutations, also known as resistance mutations that can cause a drug to be ineffective. Based on the genetic profile of the tumor, the clinician is capable to offer the best personalized treatment for each patient.

- Provide the best personalized treatment available through identification of genetic biomarkers and somatic/resistance mutations
disease progression management - Oncology applications

Disease progression management

Disease progression management

How Can We Help?

Prognostic markers can evaluate the patient’s overall outcome such as the probability of cancer recurrence after treatment, as well as to determine the progress of the disease.

- Evaluate risks of disease progression and cancer recurrence based on advanced genetic prognostic factors

better accuracy in detecting cnv and sv mutations

The assessment of somatic variants is crucial for cancer diagnostics, companion diagnostics, and target selection in drug development. The Genoox platform scales and enhances the ability to produce actionable insights from the latest scientific literature, clinical trials, and conference proceedings.

the genoox advantage

Rapid analysis
for timely diagnosis and treatment
Best practices
following AMP, NCCN & ASCO guidelines
Accelerated identification
SNV’s, CNV’s, and SV genomic alteration
Comprehensive support
supporting all relevant sequencing platforms (WGS, WES, and panels, both disease state & custom)
Multiple analysis mode
tumor only, paired normal-tumor or tumor-blood/tissue analysis
Proprietary algorithms
enabling quality results with low DNA sample volumes as often seen with FFPE - without loss in accuracy
Customizable reporting tools
to be shared with physicians and patients
Put Genoox to work for you


Find out more about our advanced tools and services: